Dr. Kehne has 25 years of pharmaceutical industry experience in the discovery and development of drugs for treating a range of central nervous system disorders, including depression, anxiety, schizophrenia, epilepsy, Parkinson's disease, Alzheimer's disease, pain, sleep disorders, and obesity. On the drug discovery side, he directed the in vivo pharmacological evaluation of compounds, many of which advanced to clinical candidate status, and has contributed to product development teams spanning from pre-IND activities to NDA submission. After receiving an undergraduate degree with honors in Neuroscience from Amherst College, he pursued doctoral training in Psychology with an emphasis in Psychopharmacology at the University of Massachusetts. He completed a postdoctoral fellowship in Biological Psychiatry at Yale University School of Medicine and joined Merrell Dow Pharmaceuticals as a scientist in the Pharmacology Department. He joined the CNS biotech company Neurogen and advanced to the level of Executive Director of Pharmacology. Recently, Dr. Kehne has worked as a consultant partnering with scientific teams to advance compounds through discovery and development. Dr. Kehne has 80 scientific publications and numerous patents and presentations at scientific meetings.
He will be supporting the research areas of Anticonvulsant Screening Program (ASP) and Cooperative Agreement Program (CAP).
Last Modified October 18, 2015